Seòmar agus comataidhean

The fleets which are currently leased by Abellio ScotRail from rolling stock owning companies (ROSCOs) are all maintained in Scotland at four main depots (Inverness, Haymarket, Corkerhill & Shields) with the split as follows:

The Franchise Contract between Scottish Ministers and Abellio specifies the service level that is required to be delivered by the Franchisee and the requirement to operate the entire train fleet in delivering the passenger services. Transport Scotland continue to monitor these contractual obligations to ensure they are being delivered.

Transport Scotland officials will consider publication of the remedial plan on receipt and agree a monitoring process with ScotRail to assess its performance and whether it is actually delivering on the plan that has been submitted. Until Transport Scotland has received and reviewed the detail of the plan a date cannot be committed for publishing an assessment into its effectiveness.

The budget of £64.2 million in 2018-19 included £54.2 million, primarily for the Bus Service Operator Grant, as well as a one-off allocation of £10.0 million of financial transaction loan facilities which were not used. In respect of 2019-20, the budget maintains the same level of investment of £54.2 million, does not include any financial transaction loan facilities, and includes an additional £3.0 million of capital grant funding to support the bus industry.

The £10m of financial transaction loan facilities previously included in 2018-19, were not used. No viable option for their use was identified with the bus industry.

I refer the member to the answer to question S5W-20840 on 16 January 2019. All answers to written parliamentary questions are available on the Parliament's website, the search facility for which can be found at http://www.parliament.scot/parliamentarybusiness/28877.aspx .

The Scottish Government is engaging with the European Commission following a complaint made on 8 June 2018 regarding our plans to reduce ferry fares to the Northern Isles.

Officials met with Commission officials in Brussels on 12 November 2018. The Scottish Government are awaiting a formal view from the Commission regarding the next steps.

The Scottish Government remains committed to pursuing all avenues to deliver reduced fares for Orkney.

High level indicative investment programmes for vessels and harbours were set out in the Ferries Plan 2013-2022 – these were and remain subject to affordability and changing priorities.

The most recent version of the Vessel Replacement and Deployment Plan was published on 31 January 2018. That plan gives an overview of how existing, planned and prospective vessels could be deployed across the Clyde and Hebrides network to deliver the commitments set out in the Scottish Ferries Plan. Work is progressing on an update to the Vessel Replacement and Deployment Plan and this will be published in the near future.

The two ferries were procured by Caledonian Maritime Assets Ltd (CMAL) through open competition to a design and build specification at a fixed price of £97m.

Ferguson Marine Engineering Ltd (FMEL) has recently submitted a contractual claim to CMAL. CMAL is considering that claim in detail.

Detailed discussions relating to contract variations or any additional costs are a matter for the contracting parties to resolve .

FMEL has formally indicated that the MV Glen Sannox (801) will be delivered during summer 2019 and the second vessel (802) in spring 2020.

CMAL have questioned whether the revised delivery dates can be achieved on the basis of current build progress. We continue to work with both parties to identify and minimise any slippage, since the importance of energy both vessels enter service on the earliest possible opportunity.

The Respiratory Care Action Plan for Scotland is in the early stages of development, and work is being taken forward with a wide range of stakeholders across the respiratory community and third sector. The Plan will set out the main priorities to support NHS Boards in the prevention, diagnosis and treatment of respiratory conditions.